KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Short-term Investments (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Short-term Investments data on record, last reported at $1.9 billion in Q3 2025.

  • For Q3 2025, Short-term Investments fell 11.49% year-over-year to $1.9 billion; the TTM value through Sep 2025 reached $1.9 billion, down 11.49%, while the annual FY2024 figure was $2.1 billion, 6.4% up from the prior year.
  • Short-term Investments reached $1.9 billion in Q3 2025 per IONS's latest filing, down from $2.0 billion in the prior quarter.
  • Across five years, Short-term Investments topped out at $2.1 billion in Q3 2024 and bottomed at $1.2 billion in Q4 2021.
  • Average Short-term Investments over 5 years is $1.8 billion, with a median of $1.9 billion recorded in 2024.
  • Peak YoY movement for Short-term Investments: fell 25.93% in 2021, then soared 37.3% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $1.2 billion in 2021, then skyrocketed by 37.3% to $1.7 billion in 2022, then rose by 12.95% to $1.9 billion in 2023, then grew by 6.4% to $2.1 billion in 2024, then dropped by 7.48% to $1.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $1.9 billion in Q3 2025, $2.0 billion in Q2 2025, and $1.9 billion in Q1 2025.